Evidence map›Paper›PMID 37425792›Full record

ArticlebioRxiv : the preprint server for biology2023

Breakthrough infections by SARS-CoV-2 variants boost cross-reactive hybrid immune responses in mRNA-vaccinated Golden Syrian Hamsters.

Juan García-Bernalt Diego, Gagandeep Singh, Sonia Jangra, Kim Handrejk, Manon Laporte, Lauren A Chang, Sara S El Zahed, Lars Pache, Max W Chang, Prajakta Warang and 6 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Juan García-Bernalt DiegoInfectious and Tropical Diseases Research Group (e-INTRO), Biomedical Research Institute of Salamanca-Research Centre for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, Spain.
Gagandeep SinghDepartment of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA.
Sonia JangraDepartment of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA.
Kim HandrejkDepartment of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA.
Manon LaporteDepartment of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA.
Lauren A ChangDepartment of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA.
Sara S El ZahedDepartment of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA.
Lars PacheNCI Designated Cancer Center, Sanford-Burnham Prebys Medical Discovery Institute, 10901 N Torrey Pines Rd, La Jolla, CA 92037, USA.
Max W ChangDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Prajakta WarangDepartment of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA.
Sadaf AslamDepartment of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA.
Ignacio MenaDepartment of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA.
Brett T WebbDepartment of Veterinary Sciences, University of Wyoming, Laramie, WY, USA.
Christopher BennerDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA.
Michael SchotsaertDepartment of Microbiology, Icahn School of Medicine at Mount Sinai New York, NY, USA.
Icahn School of Medicine at Mount Sinai · USUniversity of California San Diego · USSanford Burnham Prebys Medical Discovery Institute · USTisch Hospital · USUniversidad de Salamanca · ESUniversity of Wyoming · US

Funding

NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
SARS-CoV adaptations through a Systems Biology Lens (SYBIL)U19AI135972 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Adolfo Garcia-Sastre · 2018 to 2026
$27.2M
Combined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacyR01AI160706 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHOTSAERT, MICHAEL, WONG, PAMELA TINMOI · 2022 to 2025
$2.9M
Experimental and natural SARS-CoV-2 infection of the human pancreasR01DK130425 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOMANN, DIRK, SCHOTSAERT, MICHAEL · 2021 to 2023
$1.3M
Illumina NovaSeq 6000 Sequencing SystemS10OD026929 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEPSEN, KRISTEN LYNN · 2019 to 2019
$600k
NIAID NIH HHS 75N93021C00014NIAID NIH HHS R01 AI160706NIAID NIH HHS U19 AI135972NIDDK NIH HHS R01 DK130425NIH HHS S10 OD026929
6 · The paper itself

Abstract

Hybrid immunity to SARS-CoV-2 provides superior protection to re-infection. We performed immune profiling studies during breakthrough infections in mRNA-vaccinated hamsters to evaluate hybrid immunity induction. mRNA vaccine, BNT162b2, was dosed to induce binding antibody titers against ancestral spike, but inefficient serum virus neutralization of ancestral SARS-CoV-2 or variants of concern (VoCs). Vaccination reduced morbidity and controlled lung virus titers for ancestral virus and Alpha but allowed breakthrough infections in Beta, Delta and Mu-challenged hamsters. Vaccination primed T cell responses that were boosted by infection. Infection back-boosted neutralizing antibody responses against ancestral virus and VoCs. Hybrid immunity resulted in more cross-reactive sera. Transcriptomics post-infection reflects both vaccination status and disease course and suggests a role for interstitial macrophages in vaccine-mediated protection. Therefore, protection by vaccination, even in the absence of high titers of neutralizing antibodies in the serum, correlates with recall of broadly reactive B- and T-cell responses.

Indexed as

breakthrough infectionhybrid immunitymRNA vaccinesSARS-CoV-2variants of concern

Identifiers

PMID37425792
PMCPMC10327228
OpenAlexW4382200052

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.